This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
LEXINGTON, Mass., June 3, 2013 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that William Heiden, AMAG's chief executive officer, will present at the Jefferies 2013 Global Healthcare Conference on Wednesday, June 5, 2013 at 9:00 am ET in New York. Also, Frank Thomas, AMAG's chief operating officer, will present at the Goldman Sachs 34
th Annual Global Healthcare Conference on Thursday, June 13, 2013 at 10:00 am PT in California. The presentations will include a company overview and business update.
Live webcasts of the presentations will be accessible through the Investors section of the company's website at
www.amagpharma.com . Both webcasts will be archived on the AMAG Pharmaceuticals, Inc. website for 30 days following the conferences.
AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that manufactures and markets Feraheme® (ferumoxytol) Injection for Intravenous (IV) use in the United States. Along with driving organic growth of its lead product, AMAG intends to expand its portfolio with additional commercial-stage specialty pharmaceuticals. The company is seeking complementary products that leverage the company's commercial footprint and focus on hematology and oncology centers and hospital infusion centers. For additional company information, please visit
CONTACT: AMAG Pharmaceuticals, Inc. Contact
Amy Sullivan, 617-498-3303